Vivoryon
1 known investors
Find your way into Vivoryon
208 people in our graph share verified history with the Vivoryon team — schools, employers, funds. One of them is your warm intro.
Markus Enzelbergerunlockedknows Julia Neugebauer · together at MorphoSys (overlapped)
knows the team · via Ludwig-Maximilians-Universität München
×3knows the team · via University of Regensburg
×7knows the team · via Frankfurt School
Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.
Founders & leadership
FW
Frank WeberinChief Executive Officer / Chief Medical Officer, Executive Director
MI
Marcus IrsfeldinChief Financial Officer
JN
Julia NeugebauerinChief Operating Officer, Executive DirectorJulia Neugebauer held the role of Vice President and Global Head of Investor Relations at MorphoSys AG before becoming Chief Operating Officer at Vivoryon Therapeutics, bringing nearly two decades of biotech industry experience in investor relations and operational management across U.S. and international markets.
MS
Michael SchaefferinChief Business Officer, Executive DirectorMichael Schaeffer is Chief Business Officer and Executive Director at Vivoryon, a biotech company developing therapeutics.
Investors · 1
Competitors · 5
by search overlap
Vividion Therapeutics28 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Regeneron NASDAQ: REGN www.regeneron.com13 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Viridian Therapeutics12 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
virion12 shared keywordsVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Companies competing with Vivoryon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Updatemanilatimes.net · Aug 2026Frequently asked questions
- What does Vivoryon do?
- Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.
- Who are Vivoryon's investors?
- Vivoryon's investors include Andera Partners.